About Biohaven Pharmaceutical (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410
Debt
Debt-to-Equity RatioN/A
Current Ratio14.51%
Quick Ratio14.51%
Price-To-Earnings
Trailing P/E Ratio-5.44
Forward P/E Ratio-6.26
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book7.43
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-86.82%
Return on Assets-76.51%
Miscellaneous
Employees42
Outstanding Shares36,020,000
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical (NYSE:BHVN) issued its quarterly earnings results on Tuesday, March, 6th. The company reported ($0.75) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.33) by $0.58. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
6 brokers have issued 1 year price targets for Biohaven Pharmaceutical's stock. Their forecasts range from $25.00 to $48.00. On average, they expect Biohaven Pharmaceutical's share price to reach $37.8333 in the next twelve months. View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (4/17/2018)
- 2. Canaccord Genuity analysts commented, "We expect 0.125 and 0.15 mg/kg SVP-Rapamycin data to show robust Serum Uric Acid suppression in severe gout patients when released in April, which should boost SELB shares. We suspect that SELB may present ~n=10-11 patients per cohort, but await final data on the level of pegsiticase dosing, which was 0.2 and 0.4 mg/kg in Phase 2. Importantly, SELB has previously demonstrated that higher doses of SVP-Rapamycin show improving SUA suppression and lower antibody levels, and we would expect 0.125 and 0.15 mg/kg to improve on that trend. As a reminder, SELB showed improving SUA suppression in Phase 1b as SVP-rapamycin doses increased from 0.03 mg/kg to 0.1 mg/kg, and then to 0.15 mg/kg. Patients with SUA levels <6 mg/dL at day 30 were 0%, 70%, and 100% respectively."" (3/7/2018)
- 3. Needham & Company LLC analysts commented, "We recently hosted a series of mtgs w/ Biohaven and investors. Mgmt reiterated guidance for top-line results from both Phase 3 trials of rimegepant in Acute Migraine in 1Q18. We remain positively inclined and believe recent Allergan ubrogepant Phase 3 data set a relatively low bar for rimegepant. The open- label long-term rimegepant Phase 3 trial is half enrolled (1000/ 2000 patients) and mgmt expects to announce results YE18 (unch). Biohaven also disclosed yesterday an exclusive agreement w/ Catalent for development and commercialization of an orally disintegrating tablet (ODT) formulation of a CGRP receptor antagonist. Biohaven plans to initiate a Phase 3 trial of ODT rimegepant in the next few wks to assess potential for a more rapid impact on migraine symptoms. Data will be included in NDA and company plans to launch rimegepant w/ both ODT and tablet formulations. Reiterate BUY." (2/22/2018)
Are investors shorting Biohaven Pharmaceutical?
Biohaven Pharmaceutical saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 3,038,258 shares, an increase of 97.3% from the March 15th total of 1,539,914 shares. Based on an average daily trading volume, of 2,377,967 shares, the days-to-cover ratio is presently 1.3 days. Currently, 14.0% of the shares of the company are sold short.
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), OPKO Health (OPK), MyoKardia (MYOK), Phibro Animal Health (PAHC), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Immuron (IMRN) and Zogenix (ZGNX).
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 47)
- Mr. James Engelhart, CFO & Principal Accounting Officer (Age 54)
- Dr. Robert Berman M.D., Chief Medical Officer and VP (Age 55)
- Dr. Charles Conway Ph.D., Chief Scientific Officer (Age 56)
- Mr. John Tilton, Chief Commercial Officer (Age 50)
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Has Biohaven Pharmaceutical been receiving favorable news coverage?
Press coverage about BHVN stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 0.19 on Accern's scale. They also assigned news headlines about the company an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Biohaven Pharmaceutical's major shareholders?
Biohaven Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
BAILEY GREGORY
(8.20%) and
DOOGAN DECLAN
(6.20%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $27.18.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $994.09 million. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET SUITE 304, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biohaven Pharmaceutical (NYSE:BHVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Biohaven Pharmaceutical in the last 12 months. Their average twelve-month price target is $37.8333, suggesting that the stock has a possible upside of 39.20%. The high price target for BHVN is $48.00 and the low price target for BHVN is $25.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.8333 | $39.50 | $38.00 | $40.80 |
| Price Target Upside: | 39.20% upside | 30.58% upside | 73.28% upside | 14.74% upside |
Biohaven Pharmaceutical (NYSE:BHVN) Consensus Price Target History
Biohaven Pharmaceutical (NYSE:BHVN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Biohaven Pharmaceutical (NYSE:BHVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 34.20%
Institutional Ownership Percentage: 61.84%
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Robert Berman | Insider | Sell | 35,000 | $24.66 | $863,100.00 | |  |
| 3/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.11 | $1,053,850.00 | | |
| 3/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.87 | $164,350.00 | | |
| 2/21/2018 | James Engelhart | CFO | Sell | 538 | $29.60 | $15,924.80 | 3,038 | |
| 2/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.42 | $1,064,700.00 | | |
| 2/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.78 | $163,900.00 | 5,000 | |
| 1/31/2018 | Gregory Bailey | Director | Sell | 50,000 | $33.71 | $1,685,500.00 | 2,516,701 | |
| 1/22/2018 | Gregory Bailey | Director | Sell | 49,000 | $30.76 | $1,507,240.00 | 2,583,289 | |
| 1/22/2018 | James Engelhart | CFO | Sell | 10,000 | $32.50 | $325,000.00 | 13,576 | |
| 1/19/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,119 | $30.03 | $1,054,623.57 | | |
| 1/18/2018 | Declan Doogan | Director | Sell | 128,058 | $26.95 | $3,451,163.10 | 2,583,289 | |
| 1/16/2018 | Gregory Bailey | Director | Sell | 40,000 | $26.52 | $1,060,800.00 | | |
| 1/12/2018 | Declan Doogan | Director | Sell | 121,942 | $26.78 | $3,265,606.76 | | |
| 1/10/2018 | Declan Doogan | Director | Sell | 40,362 | $27.69 | $1,117,623.78 | | |
| 1/10/2018 | Robert Berman | Insider | Sell | 35,000 | $27.52 | $963,200.00 | | |
| 1/9/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 84,881 | $30.06 | $2,551,522.86 | 6,278,504 | |
| 1/5/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 22,996 | $30.03 | $690,569.88 | 6,278,504 | |
| 1/4/2018 | Gregory Bailey | Director | Sell | 50,000 | $28.71 | $1,435,500.00 | 1,187,275 | |
| 1/3/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,650 | $28.61 | $1,019,946.50 | 124,371 | |
| 1/2/2018 | Kimberly Gentile | VP | Sell | 5,000 | $27.60 | $138,000.00 | 5,000 | |
| 12/20/2017 | Gregory Bailey | Director | Sell | 39,430 | $26.31 | $1,037,403.30 | 1,234,077 | |
| 12/19/2017 | Robert Berman | Insider | Sell | 10,000 | $24.10 | $241,000.00 | | |
| 12/11/2017 | Robert Berman | Insider | Sell | 25,000 | $21.28 | $532,000.00 | | |
| 12/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $21.99 | $109,950.00 | | |
| 11/30/2017 | Gregory Bailey | Director | Sell | 9,970 | $25.48 | $254,035.60 | 1,262,759 | |
| 11/27/2017 | Gregory Bailey | Director | Sell | 20,600 | $25.92 | $533,952.00 | 1,289,699 | |
| 11/24/2017 | Gregory Bailey | Director | Sell | 600 | $26.02 | $15,612.00 | 1,289,699 | |
| 11/14/2017 | Robert Berman | Insider | Sell | 160,000 | $25.76 | $4,121,600.00 | | |
| 11/10/2017 | James Engelhart | CFO | Sell | 30,538 | $26.58 | $811,700.04 | 25,176 | |
| 11/9/2017 | Robert Berman | Insider | Sell | 27,423 | $26.60 | $729,451.80 | | |
| 11/1/2017 | John Tilton | Insider | Sell | 30,000 | $29.25 | $877,500.00 | 30,000 | |
| 11/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $29.28 | $146,400.00 | 5,000 | |
| 11/1/2017 | Vlad Coric | CEO | Sell | 150,000 | $29.41 | $4,411,500.00 | | |
| 5/9/2017 | Albert Cha | Director | Buy | 470,000 | $17.00 | $7,990,000.00 | | |
| 5/9/2017 | James Engelhart | CFO | Buy | 2,500 | $17.00 | $42,500.00 | 3,576 | |
| 5/9/2017 | Robert Berman | Insider | Buy | 50 | $17.00 | $850.00 | | |
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) News Headlines
| Source: |
|
Biohaven Pharmaceutical (NYSE:BHVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biohaven Pharmaceutical (NYSE:BHVN) Income Statement, Balance Sheet and Cash Flow Statement
Biohaven Pharmaceutical (NYSE BHVN) Stock Chart for Saturday, April, 21, 2018
Loading chart…
